Aldeyra Therapeutics (ALDX) risk factors, FY2024 10-K

Other

1. 01Summary of Risks Related to our Business
2. 02We will require substantial additional financing, and a failure to obtain this necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce, or terminate our product development, other operations or commercialization efforts

Risks Related to the Potential Development and Commercialization of Reproxalap and our Product Candidates

1. 03we may not be able to obtain, maintain, or enforce our patents and other intellectual property rights
2. 04Any regulatory approval of reproxalap, once obtained, may be withdrawn. Ultimately, the failure to obtain and maintain regulatory approvals would prevent reproxalap from being marketed and would have a material adverse effect on our business
3. 05If the Option is exercised and the Collaboration Agreement is executed, then pursuant to the terms of the Collaboration Agreement, we would work closely with AbbVie to execute a commercialization plan for reproxalap in the United States, and the commercialization plan may never achieve desired outcomes
4. 06Any termination or suspension of, or delays in the commencement or completion of, our clinical trials could result in increased costs to us, delay or limit our ability to generate revenue, and adversely affect our commercial prospects
5. 07one or more IRBs refusing to approve, suspending, or terminating a clinical trial at an investigational site, precluding enrollment of additional subjects, or withdrawing approval of the trial
6. 08our prioritization of other indications or product candidates for advancement
7. 09the approval policies, standards, or regulations of such authorities may significantly change in a manner rendering our or any of our future development partners’ clinical data insufficient for approval
8. 10Because the Company has no experience in commercializing pharmaceutical products, there is a limited amount of information about us upon which to evaluate our product candidates and business prospects
9. 11gain broad market acceptance for our product candidates
10. 12The results of preclinical studies and earlier clinical trials are not always predictive of future results. Any product candidate we or any of our future development partners advance into clinical trials may not have favorable results in later clinical trials, if any, or receive regulatory approval
11. 13Because some of our product candidates are, to our knowledge, new chemical entities, it is difficult to predict the time and cost of development and our ability to successfully complete clinical development of these product candidates and obtain the necessary regulatory approvals for commercialization
12. 14To preserve trial integrity, clinical data from the initial parts of adaptive clinical trials may not be disclosed
13. 15We may find it difficult to enroll patients in our clinical trials or identify patients during commercialization (if our products are approved by regulatory agencies) for product candidates addressing orphan or rare diseases
14. 16Any product candidate we or any of our future development partners advance into clinical trials may cause unacceptable adverse events or have other properties that may delay or prevent regulatory approval or commercialization or limit commercial potential
15. 17The occurrence of any event or penalty described above may inhibit our ability to commercialize our product candidates and generate revenue
16. 18Even if we receive regulatory approval for reproxalap or any other product candidate, we or are partners, if any, still may not be able to successfully commercialize, and the revenue that we generate from its sales, if any, could be limited
17. 19the willingness of patients to pay out-of-pocket in the absence of third-party coverage
18. 20If the market opportunities for reproxalap and our other product candidates are smaller than we believe they are, and if we are not able to successfully identify patients and achieve significant market share, our revenue may be adversely affected, and our business may suffer
19. 21Reimbursement may be limited or unavailable in certain market segments for our product candidates, which could make it difficult for us to sell our product candidates profitably
20. 22neither experimental nor investigational
21. 23We are subject to a multitude of manufacturing risks, any of which could substantially increase our costs and limit supply of our products
22. 24The manufacturing facilities in which our products are made could be adversely affected by equipment failures, labor shortages, natural disasters, power failures, or numerous other factors
23. 25harm our business. In addition, failure of CMOs to comply with regulatory and quality requirements could delay manufacturing or the review of our marketing applications
24. 26Issues with product quality could have a material adverse effect upon our business, subject us to regulatory actions and cause a loss of customer confidence in us or our products
25. 27If we are unable to enter into agreements with third parties to market, sell, and distribute our product candidates, we may be unable to generate any revenue
26. 28condition authorized for marketing in the EU or if such a method exists, the product will be of significant benefit to those affected by the condition, as defined in Regulation (EC) 847/2000
27. 29The holder of the marketing authorization for the original orphan medicinal product cannot supply sufficient quantities of orphan medicinal product
28. 30The UK’s regulatory legal framework provides for similar periods of protection, namely regulatory data protection, marketing protection and market exclusivity
29. 31The FDA’s ability to review and approve new products may be hindered by a variety of factors, including budget and funding levels; ability to hire and retain key personnel; and statutory, regulatory, and policy changes
30. 32Due to the recent change in presidential administration, we face uncertainty regarding potential regulatory developments that may adversely affect our business
31. 33Failure to obtain regulatory approval in foreign jurisdictions would prevent us from marketing and commercializing our products abroad and may limit our ability to generate revenue from product sales

Risks Related to our Financial Position and Capital Requirements

1. 34We have incurred significant operating losses since inception, and we expect to incur significant losses over the next several years. We may never become profitable or, if achieved, be able to sustain profitability
2. 35may in the future enter into licensing and funding arrangements with third parties that may impose milestone payment, royalty, insurance, or other obligations on us
3. 36there are any third‑party challenges to our intellectual property portfolio, or the need arises to defend against intellectual property‑related claims
4. 37obtaining, maintaining, and protecting our intellectual property rights
5. 38We will require substantial additional financing, and a failure to obtain the necessary capital when needed on acceptable terms, or at all, could force us to delay, limit, reduce or terminate our product development, other operations or commercialization efforts
6. 39the costs of obtaining, maintaining, and enforcing our patents and other intellectual property rights
7. 40Our quarterly operating results may fluctuate significantly
8. 41derivative instruments recorded at fair value
9. 42Raising additional capital may cause dilution to stockholders, restrict our operations, or require us to relinquish rights to its technologies or product candidates
10. 43We may allocate our cash, cash equivalents, and marketable securities in ways that you or other stockholders may not approve
11. 44The terms of our secured debt facility require us to meet certain operating covenants and place restrictions on our operating and financial flexibility. If we raise additional capital through debt financing, the terms of any new debt could further restrict our ability to operate our business
12. 45Our ability to use net operating loss carryforwards and tax credit carryforwards to offset future taxable income may be limited as a result of transactions involving our common stock
13. 46Governments may impose price controls, which may adversely affect our future profitability
14. 47Business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses
15. 48Global economic conditions may have an adverse effect on our business
16. 49secure necessary financing in a timely manner and on favorable terms could materially and adversely affect our stock price and force us to delay or abandon clinical development plans
17. 50If we engage in an acquisition, reorganization, or business combination, we will incur a variety of risks that could adversely affect our business operations or our stockholders
18. 51the potential loss of key employees of acquired businesses

Risks Related to our Reliance on Third Parties

1. 52We rely and will continue to rely on outsourcing arrangements for many of our activities, including clinical development, commercial readiness preparations, and supply of reproxalap and our other product candidates
2. 53Some of our product candidates may be studied in clinical trials co-sponsored by organizations or agencies other than us, or in investigator-initiated clinical trials, which means we have minimal or no control over the conduct of such trials
3. 54We rely completely on third parties to supply drug substance and manufacture drug product for our clinical trials and preclinical studies. We intend to rely on other third parties to produce commercial supplies of product candidates, and our dependence on third parties could adversely impact our business
4. 55We may not be successful in establishing and maintaining development, commercial, or other strategic partnerships, which could adversely affect our ability to develop and commercialize product candidates
5. 56product candidate are below expectations. Any delay in entering into development partnership agreements or collaborations related to our product candidates could delay the development and commercialization of our product candidates and reduce competitiveness, if approved
6. 57We may not realize the benefits of our current or future strategic alliances
7. 58Our internal computer systems, or those of our development partners, third-party clinical research organizations, or other contractors or consultants, may fail or suffer security breaches, which could result in a material disruption of our product development programs

Risks Relating to Our Intellectual Property

1. 59Our success depends on our and our licensors' ability to protect our intellectual property and our proprietary technologies
2. 60countries other than the United States may have patent laws less favorable to patentees than those upheld by United States courts, allowing foreign competitors a better opportunity to create, develop, and market competing product candidates
3. 61Claims by third parties that we infringe their proprietary rights may result in liability for damages or prevent or delay our developmental and commercialization efforts
4. 62require us to enter into royalty or licensing agreements
5. 63Our issued patents could be found invalid or unenforceable if challenged in court
6. 64We may fail to comply with any of our obligations under existing or future agreements pursuant to which we license or acquire rights or technology, which could result in the loss of rights or technology that are material to our business
7. 65We may be subject to claims that we have wrongfully hired an employee from a competitor or that we or our employees, consultants, or agents have wrongfully used or disclosed alleged confidential information or trade secrets of their former employers
8. 66If we do not obtain protection under the Hatch-Waxman Amendments by extending the patent terms and obtaining data exclusivity for our product candidate, our business may be materially harmed
9. 67If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our markets of interest and our business may be adversely affected
10. 68Changes in United States patent law could diminish the value of patents in general, thereby impairing our ability to protect our product candidates
11. 69We may not be able to protect our intellectual property rights throughout the world
12. 70We and the third parties with whom we work are increasingly utilizing social media tools as a means of communication both internally and externally, and noncompliance with applicable requirements, policies, or contracts due to social media use or negative posts or comments could have an adverse effect on our business

Risks Related to Employee Matters and Managing Growth

1. 71We are highly dependent on the services of our senior management team and certain key consultants
2. 72If we fail to attract and retain senior management, we may be unable to successfully develop or commercialize our product candidates
3. 73In order to commercialize the product candidates not subject to existing partnership agreements, we will need to substantially grow the size of our organization. We may encounter difficulties in managing our growth and expanding our operations successfully

Risks Related to Other Legal or Regulatory Matters

1. 74Our business is subject to political, economic, legal, and social risks, which could adversely affect our business
2. 75currency transfer and other restrictions and regulations that may limit our ability to sell certain products or repatriate profits to the United States
3. 76Any changes related to political, economic, legal, and social factors could adversely affect any business operations that we conduct outside the United States
4. 77investigations or actions, litigation, and significant fines and penalties, which could adversely affect our business, financial condition, and reputation
5. 78transfers of personal data from the EU to the U.S., and added further uncertainty and complexity to the use of standard contractual clauses as a compliance mechanism for transfers of personal data outside the EU
6. 79Current and future legislation may increase the difficulty and cost for us to obtain regulatory and marketing approval of and commercialize our product candidates, alone or with others, and may affect the prices we may obtain
7. 80the availability of capital
8. 81state and foreign laws that govern the privacy and security of health information in some circumstances, many of which differ from each other in significant ways and often are not preempted by HIPAA, thus complicating compliance efforts
9. 82If we market products in a manner that violates healthcare fraud and abuse laws, or if we violate government price reporting laws, we may be subject to civil or criminal penalties
10. 83If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of reproxalap or our other product candidates
11. 84a decline in our stock price
12. 85We and our development partners, third-party manufacturers, and suppliers use biological materials and may use hazardous materials, and any claims relating to improper handling, storage, or disposal of these materials could be time consuming or costly
13. 86We and any of our future development partners will be required to report to regulatory authorities if any of our approved products cause or contribute to adverse medical events, and any failure to do so would result in sanctions that would materially harm our business
14. 87penalties, or other remedial measures and legal expenses, any of which could adversely affect our business, results of operations and financial condition
15. 88Our employees, independent contractors, vendors, principal investigators, contract research organizations (CROs), and consultants may engage in misconduct or other improper activities, including noncompliance with regulatory standards, regulatory requirements, and insider trading
16. 89failures to report financial information or data accurately
17. 90We are subject to litigation risks
18. 91We are, and could in the future be, subject to securities class action litigation
19. 92Our insurance policies are expensive and protect us only from some business risks, which leaves us exposed to significant uninsured liabilities
20. 93U.S. federal and state income tax reform could adversely affect us

Risks Related to Our Common Stock

1. 94In the absence of an active trading market for our common stock, investors may not be able to resell their shares at or above the price at which the shares were purchased
2. 95The trading price of the shares of our common stock has been and is likely to continue to be highly volatile, and purchasers of our common stock could incur substantial losses
3. 96intellectual property, product liability, or other litigation against us
4. 97Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a delisting of our common stock
5. 98Because a small number of our existing stockholders own a substantial percentage of our outstanding common stock, your ability to influence corporate matters will be limited
6. 99If our shares become subject to the penny stock rules, it would become more difficult to trade our shares
7. 100We do not intend to pay dividends on our common stock and, consequently, your ability to achieve a return on your investment will depend on appreciation in the price of our common stock
8. 101A substantial number of shares of our common stock could be sold into the public market in the near future, which could depress our stock price
9. 102We are a smaller reporting company, and we cannot be certain if the reduced reporting requirements applicable to smaller reporting companies will make our common stock less attractive to investors
10. 103We are incurring significant increased costs and demands upon management as a result of operating as a public company
11. 104If we fail to maintain proper and effective internal control over financial reporting in the future, our ability to produce accurate and timely financial statements could be impaired, which could harm our operating results, investors’ views of us and, as a result, the value of our common stock
12. 105If we are unable to establish and maintain effective internal controls it could have a material adverse effect on our business, financial condition, results of operations, or cash flows
13. 106If securities or industry analysts do not continue to publish research or reports or publish unfavorable research or reports about our business, our stock price and trading volume could decline
14. 107Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
15. 108establishing advance notice requirements for nominations for election to the board of directors or for proposing matters that can be acted upon at stockholder meetings
16. 109Our business could be negatively affected as a result of the actions of activist stockholders